| First Author | Li P | Year | 2025 |
| Journal | Cell Rep | Volume | 44 |
| Issue | 6 | Pages | 115793 |
| PubMed ID | 40478733 | Mgi Jnum | J:377850 |
| Mgi Id | MGI:8222274 | Doi | 10.1016/j.celrep.2025.115793 |
| Citation | Li P, et al. (2025) RORgammat is crucial for gut homeostasis by regulating the expression of HB-EGF rather than IL-22 in activated ILC3s. Cell Rep 44(6):115793 |
| abstractText | RORgammat inhibition shows potential for treating T helper 17 (Th17) cell-related inflammatory disorders. However, there is a lack of a comprehensive understanding of its influence on the immune system. RORgammat also serves as the master regulator of type 3 innate lymphoid cells (ILC3s). Although previous studies indicated that it might not be essential for ILC3 activation, our single-cell RNA sequencing analysis reveals its fundamental participation. By utilizing an Il22(Cre/+)Rosa26(LSL-Tdtomato)Rorc(fl/fl) (interleukin [IL]-22-fate mapping [FM](DeltaRorc)) mouse model, we discovered that genetic deletion of Rorc does not completely eliminate ILC3s. Only the lymphoid tissue inducer (LTi) subset experiences a reduction. Additionally, the "ex-ILC3s" following Rorc deletion still preserve ILC3 characteristics and produce sufficient IL-22 to maintain gut health and prevent pathogen invasion. Nevertheless, RORgammat is found to be crucial for heparin-binding epidermal growth factor (HB-EGF) production in activated ILC3s, which is of great significance in alleviating colitis. Thus, our findings clarify the role of RORgammat in ILC3s, thereby providing insights for the clinical evaluation of RORgammat inhibition. |
